An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Phase of Trial: Phase II
Latest Information Update: 01 Dec 2017
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 05 May 2015 Results published in the Alexion Pharmaceuticals Media Release.
- 05 May 2015 According to Alexion Pharmaceuticals media release, the data from post-hoc sub-analysis was presented at American Transplant Congress (ATC) 2015.
- 23 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History